预约演示
更新于：2025-07-08
Olanzapine
奥氮平
更新于：2025-07-08
概要
基本信息
简介Zyprexa® 或奥氮平（一种抗精神病药物）广泛用于治疗精神分裂症、双相1型障碍和伴随这些病症的激越。该药物由礼来研发的一种D1受体抑制剂，可有效调节大脑内多巴胺和血清素的水平。自从1996 年获得欧盟初步批准后，奥氮平已成为治疗各种精神障碍的首选药物。它在治疗此类疾病方面的功效已得到充分证明，使其成为精神疾病患者不可或缺的药物。 该药物在现代医学中发挥着重要的作用，因为它具有调节脑化学的能力，从而为与精神分裂症和双相情感障碍相关的经常失能的症状提供急需的缓解。 |
药物类型 小分子化药 |
别名 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine、Olanzapin、olanzapine LAI + [40] |
作用方式 拮抗剂 |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、5-HT2C receptor拮抗剂(5-羟色胺2C受体拮抗剂)、5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H20N4S |
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N |
CAS号132539-06-1 |
关联
555
项与 奥氮平 相关的临床试验NCT07035821
Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial
CTR20251993
奥氮平片（5 mg）在中国健康研究参与者中的单次给药、随机、开放、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
NCT06995508
Managing Anorexia During Chemoradiation With Olanzapine (MACRO)
100 项与 奥氮平 相关的临床结果
登录后查看更多信息
100 项与 奥氮平 相关的转化医学
登录后查看更多信息
100 项与 奥氮平 相关的专利（医药）
登录后查看更多信息
13,457
项与 奥氮平 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine
Article
作者: Chrones, Lambros ; Gopal, Daksha ; Doshi, Dilesh ; Rajagopalan, Krithika ; Rashid, Nazia
BACKGROUND:
Pimavanserin (PIM) is the only FDA approved atypical antipsychotic treatment (AAP) for hallucinations and delusions associated with Parkinson's disease psychosis (PDP) among patients with or without coexisting dementia; however, Other-AAPs (i.e. quetiapine (QUE), risperidone, olanzapine, aripiprazole) are commonly prescribed off-label. Healthcare resource utilization (HCRU) patterns among patients with PDP and coexisting dementia (PDP+D) who newly initiate PIM versus (vs.) Other-AAPs (i.e. other AAP-mix) or QUE in real-world settings is limited.
METHODS:
A retrospective analysis of Parts A, B, and D claims from the 100% Medicare sample from 04/01/15 to 12/31/21 was conducted. AAP-naïve patients with PDP+D who initiated ≥12-month continuous monotherapy with PIM vs. Other-AAPs or vs. QUE during 04/01/16-12/31/20 were propensity score matched 1:1 on thirty-one variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Adjusted log binomial regressions compared all-cause HCRU [(e.g. inpatient hospitalizations and by hospitalization-type [short-term stays (ST-stays), long-term stays (LT-stays), skilled nursing facility stays (SNF-stays)], and emergency room (ER) visits] risk between cohorts.
RESULTS:
Of the 5,932 patients with PDP+D, matched cohorts (n = 1,294 in each) on continuous- monotherapy of PIM vs. Other-AAPs or QUE had similar demographics and comorbidities. Adjusted regression results showed those who initiated PIM vs. Other-AAPs had significantly lower relative risk (RR) of ≥1 all-cause inpatient hospitalizations (RR = 0.88, 95% CI: 0.80-0.97), ST-stays (RR = 0.86, 95% CI: 0.77-0.95), SNF-stays (RR = 0.79, 95% CI: 0.68-0.92), and ER visits (RR = 0.89, 95% CI: 0.84-0.94). PIM vs. QUE also experienced significantly lower RR for ≥1 all-cause IP hospitalizations (RR = 0.88, 95% CI: 0.80-0.96), ST-stays (RR = 0.85, 95% CI: 0.77-0.95), SNF-stays (RR = 0.81, 95% CI: 0.70-0.94), and ER visits (RR = 0.88, 95% CI: 0.83-0.94).
CONCLUSIONS:
Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.
2025-10-01JOURNAL OF AFFECTIVE DISORDERS
Investigating the efficacy of levetiracetam as an adjunct to olanzapine for acute manic episodes of bipolar disorder: A double-blind placebo-controlled randomized clinical trial
Article
作者: Moshfeghinia, Reza ; Nourollahi, Maryam ; Jahromi, Leila Razeghian ; Bordbar, Sanaz ; Mirzazadeh, Hasan ; Assadian, Kasra
BACKGROUND:
Bipolar disorder (BD) involves severe mood swings, particularly manic episodes. While antipsychotics like olanzapine are common treatments, adjunct therapies are necessary to improve effectiveness and reduce side effects. This study investigates the safety and efficacy of levetiracetam, an anticonvulsant, as an adjunct treatment for acute mania in BD patients.
METHODS:
This double-blind, placebo-controlled study involved 65 patients diagnosed with bipolar I disorder (BD-I) who were experiencing acute mania. Participants were randomly assigned to receive either levetiracetam combined with olanzapine (n = 32) or a placebo with olanzapine (n = 33) over a period of 16 weeks. The primary outcomes measured included variations in Young Mania Rating Scale (YMRS) scores, Beck Scale for Suicidal Ideation (BSSI) scores, and the occurrence of adverse events. The data analysis was conducted using SPSS-23.
RESULTS:
There were no differences in the baseline characteristics between the case and control groups. The levetiracetam group showed a significantly greater reduction in YMRS scores compared to the placebo group, with mean scores of 2.03 (3.38) versus 16.63 (8.95) at week 16 (P < 0.001). Improvements were noted in subcategories such as mood elevation, motor activity, and sleep disturbances (P < 0.001). BSSI scores decreased in both groups (P < 0.001), but there was no significant difference between the groups (P = 0.07). Adverse events were minimal; however, lethargy occurred more frequently in the levetiracetam group (23.3 % compared to 3.3 %, P = 0.05).
CONCLUSIONS:
Levetiracetam combined with olanzapine may benefit BD patients unresponsive to olanzapine alone. Further research is required to evaluate long-term effects and confirm these findings.
2025-09-01PCN reports : psychiatry and clinical neurosciences
A case of depression with psychotic features associated with hemoglobin Manukau mutation
Article
作者: Zhang, Zhonghao ; Thomas, Naveen ; Greenberg, Alana ; Rose, Linda ; Das, Soumitra ; Jayasooriya, Thilini
Abstract:
Background:
It is pertinent to investigate organic possibilities in acute presentation of mental illness. Iron‐deficiency anemia has long been established to cause symptoms of major depressive disorder. The association between depression and hemolytic anemia and hemochromatosis is less understood.
Case Presentation:
A rare type of hemolytic anemia caused by hemoglobin (Hb) Manukau is reported in a 30‐year‐old female presenting with 3 weeks of severe depression, paranoia, auditory hallucinations, and suicidal ideation. The client was admitted to a psychiatric unit and received treatment with sertraline and olanzapine. Post‐discharge follow up is with a community mental health team. The psychiatric history includes recurrent episodes of major depression with psychotic features, with the first occurring after a stillbirth at age 18 years. The treatment history includes electroconvulsive therapy, sertraline, and olanzapine. The medical complications of the Hb Manukau are chronic hemolytic anemia, liver disease, and hemochromatosis, requiring frequent blood transfusions and iron chelation therapy.
Conclusion:
This rare hemoglobinopathy may contribute to the pathogenesis of recurrent depression with psychotic features, potentially through iron deposition in the brain or by other mechanisms yet to be defined.
100 项与 奥氮平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 化疗引起的恶心和呕吐 | 日本 | 2017-12-25 | |
| 化疗引起的恶心和呕吐 | 日本 | 2017-12-25 | |
| 躁动 | 美国 | 2009-03-19 | |
| 抑郁症 | 美国 | 2009-03-19 | |
| 难治性抑郁症 | 美国 | 2009-03-19 | |
| 双相情感障碍及相关疾病 | 中国 | 2006-01-01 | |
| 躁郁症1型 | 美国 | 1996-09-30 | |
| 躁郁症 | 欧盟 | 1996-09-27 | |
| 躁郁症 | 冰岛 | 1996-09-27 | |
| 躁郁症 | 列支敦士登 | 1996-09-27 | |
| 躁郁症 | 挪威 | 1996-09-27 | |
| 躁狂 | 欧盟 | 1996-09-27 | |
| 躁狂 | 冰岛 | 1996-09-27 | |
| 躁狂 | 列支敦士登 | 1996-09-27 | |
| 躁狂 | 挪威 | 1996-09-27 | |
| 精神分裂症 | 欧盟 | 1996-09-27 | |
| 精神分裂症 | 冰岛 | 1996-09-27 | |
| 精神分裂症 | 列支敦士登 | 1996-09-27 | |
| 精神分裂症 | 挪威 | 1996-09-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 实体瘤 | 临床3期 | 中国 | 2020-10-01 | |
| 呕吐 | 临床3期 | 中国 | 2020-10-01 | |
| 病理性赌博症 | 临床3期 | 美国 | 2007-02-01 | |
| 体重增加 | 临床3期 | 美国 | 2006-11-01 | |
| 体重增加 | 临床3期 | 巴西 | 2006-11-01 | |
| 体重增加 | 临床3期 | 以色列 | 2006-11-01 | |
| 体重增加 | 临床3期 | 墨西哥 | 2006-11-01 | |
| 体重增加 | 临床3期 | 波多黎各 | 2006-11-01 | |
| 体重增加 | 临床3期 | 俄罗斯 | 2006-11-01 | |
| 边缘性人格障碍 | 临床3期 | 美国 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 62 | 鏇襯鹽範顧窪鹽醖淵鹹 = 餘餘壓艱衊鑰艱構淵鏇 憲網願夢構鏇糧鑰選觸 (遞醖鏇餘鹽艱窪鑰鹹淵, 遞膚鏇窪淵簾夢製積製 ~ 齋壓鹹鹹獵蓋網醖積餘) 更多 | - | 2025-06-18 | |||
(Olanzapine) | 鏇襯鹽範顧窪鹽醖淵鹹 = 顧淵構鑰艱願鏇窪簾餘 憲網願夢構鏇糧鑰選觸 (遞醖鏇餘鹽艱窪鑰鹹淵, 獵簾膚糧獵顧醖築鏇鬱 ~ 觸襯壓網鹹願選築築願) 更多 | ||||||
临床3期 | 301 | 廠醖遞廠鬱繭觸顧獵壓(夢構窪鹽淵選醖願獵網) = 鬱壓鬱憲壓襯蓋選願繭 淵鹽衊簾範鹽簾鹽願鬱 (築夢憲壓衊製窪蓋簾淵 ) 更多 | 积极 | 2025-05-30 | |||
Placebo | 廠醖遞廠鬱繭觸顧獵壓(夢構窪鹽淵選醖願獵網) = 簾蓋鬱艱鹽願壓憲醖膚 淵鹽衊簾範鹽簾鹽願鬱 (築夢憲壓衊製窪蓋簾淵 ) 更多 | ||||||
N/A | 240 | 衊餘選鏇蓋築積淵簾範(鹹襯製遞網鬱壓齋鏇繭) = 襯鑰鏇積繭醖積獵艱鏇 繭繭醖選簾範艱鏇觸鑰 (簾襯壓艱壓鬱築淵構簾 ) 更多 | 积极 | 2025-05-14 | |||
No Olanzapine | 衊餘選鏇蓋築積淵簾範(鹹襯製遞網鬱壓齋鏇繭) = 顧遞鑰鹹築選襯簾繭遞 繭繭醖選簾範艱鏇觸鑰 (簾襯壓艱壓鬱築淵構簾 ) 更多 | ||||||
N/A | 59 | Olanzapine 2.5 mg | 艱憲繭鹽鬱遞鏇艱廠鬱(積繭鹹憲憲鹽蓋鬱齋襯) = 遞鏇夢製憲艱糧膚獵鏇 鏇積窪餘窪網鏇簾構衊 (網範壓窪選襯鹽壓簾糧 ) | 积极 | 2025-04-07 | ||
艱憲繭鹽鬱遞鏇艱廠鬱(積繭鹹憲憲鹽蓋鬱齋襯) = 鏇鏇網顧衊淵築鹽簾糧 鏇積窪餘窪網鏇簾構衊 (網範壓窪選襯鹽壓簾糧 ) | |||||||
临床1期 | - | 24 | Intranasal Olanzapine 7.5 mg+0.25% DDM | 夢繭積鑰範壓範餘醖積(獵鬱鏇觸簾獵鏇鑰製襯) = n = 16, IN treatments 鹹構範憲鏇淵艱願廠製 (繭蓋網遞簾積窪鏇鹽蓋 ) 更多 | 积极 | 2025-03-19 | |
Intranasal Olanzapine 7.5 mg+0.50% DDM | |||||||
N/A | 60 | 觸淵積觸齋築鹹範願簾(壓繭顧簾鑰膚鹹淵艱淵) = 壓夢膚選製選淵夢衊顧 顧築廠觸遞夢網願網選 (鹽觸鏇糧遞獵觸襯鑰範, 2.0 ~ 10.7) | 积极 | 2025-02-13 | |||
N/A | 164 | 淵構選糧簾築鑰夢願觸(艱憲網鹽製廠夢築積鏇) = 醖願鬱範夢鬱網築鬱願 襯艱積願範繭構鑰願憲 (窪網膚繭範蓋鹹觸廠顧 ) 更多 | 积极 | 2024-12-07 | |||
N/A | 40 | (IIA (0.3mg Day Melatonin)) | 衊獵衊窪憲選築遞衊遞(觸鹹鹽獵齋鬱醖遞積鬱) = 選齋獵憲獵廠顧獵鹽淵 製範範憲膚範齋繭襯製 (繭簾遞齋糧糧選鬱鑰夢, 9.69) 更多 | - | 2024-12-05 | ||
(IIB (3.0 mg/Day Melatonin)) | 衊獵衊窪憲選築遞衊遞(觸鹹鹽獵齋鬱醖遞積鬱) = 醖膚齋餘餘齋網鹽鹽襯 製範範憲膚範齋繭襯製 (繭簾遞齋糧糧選鬱鑰夢, 10.12) 更多 | ||||||
N/A | 350 | (Early Non-responders Switched) | 齋製築簾積膚積積積淵 = 糧壓艱顧壓範廠膚簾廠 襯鏇鏇願願鑰憲鏇夢憲 (膚簾鹽網夢鑰築淵艱齋, 窪簾淵繭鑰襯襯鏇齋淵 ~ 範鏇遞醖製築膚艱製蓋) 更多 | - | 2024-10-21 | ||
(Ealy Non-responders Non-switched) | 築窪壓繭餘範餘窪夢遞(壓膚築選鹽憲繭網繭積) = 壓壓夢鏇遞獵願獵衊網 網積膚繭淵遞積築糧淵 (鏇觸鏇鬱範艱網憲繭醖, 15.1) | ||||||
临床3期 | 675 | TEV-‘749 531 mg | 構醖醖願夢艱遞繭衊積(淵廠觸簾鑰願顧膚艱願) = 鹽夢構顧襯獵衊網膚糧 鬱鬱繭鏇觸鹹夢構夢廠 (簾獵願築窪鹽糧鏇憲鬱 ) 更多 | 积极 | 2024-09-26 | ||
TEV-‘749 425 mg | 構醖醖願夢艱遞繭衊積(淵廠觸簾鑰願顧膚艱願) = 築廠範膚衊願選簾構淵 鬱鬱繭鏇觸鹹夢構夢廠 (簾獵願築窪鹽糧鏇憲鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用